ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl

ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 9.4 as on 03-02-2023

Fund Performance

Fund Performance as on (19-Jan-23)

Return
1M
3M
6M
1Y
This Fund
-2.8%
-7.3%
1.3%
-4.8%
Benchmark
-2.3%
2.2%
9.6%
-0.5%
Category
-3.4%
-8.1%
-1.7%
-8.3%
About the Fund

ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is an equity fund. This fund was started on  11 November, 2021. The fund is managed by Rohan Korde, Tanay Gabhawala, Dhimant Shah. The fund could potentially beat inflation in the long-run.

Key parameters

1) ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl has a NAV of 9.3704 as on 03-02-2023.

2) ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl has 165 Cr worth of assets under management (AUM) as on 31-12-2022 and is less than category average.

3) The fund has an expense ratio 0.3 %.

Fund Overview

Expense ratio
Expense ratio
0.3%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹165 Cr
Inception Date
Inception Date
11 November, 2021
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹500
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
0%

Fund Distribution as on (31-Dec-22)

  • Equity 98.9%
  • Debt & Cash 1.1%
Size breakup
Large cap
54.1%
Mid cap
23.7%
Small cap
18.1%

Sector Allocation

Dec'22

Nov'22

Oct'22

Health

96.4%

Basic Materials

3.6%

Top Holdings as on (31-Dec-22)

  • Equity
Equity Holdings28

What changed

in last one month
  • Scheme
  • Portfolio
AUM has remained same in the last 1M
Dec'22 return underperformed benchmark

Change in AUM

Dec'22
₹ 164.6 Cr
Nov'22
₹ 164.6 Cr
Oct'22
₹ 171.5 Cr

Fund Returns vs Benchmark

Jan'23
3.78%
5.37%
Dec'22
0.43%
2.63%
Nov'22
3.78%
5.37%
Fund Return
Benchmark Return

Concentration Analysis as on (31-Dec-22)

Fund
Dec'22
Nov'22
Oct'22
No of Holdings
28
29
32
Top 5 Company Concentration
52.5%
51.9%
50.8%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (22.7%)
Sun Pharmaceuticals Industries Ltd (22.2%)
Sun Pharmaceuticals Industries Ltd (21.6%)
No of Sectors
3
4
4
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (95.3%)
Health (94.2%)
Health (92.8%)

Fund Manager

Rohan Korde

Rohan Korde

Fund Manager of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl, since 11 November 2021
Tanay Gabhawala

Tanay Gabhawala

Fund Manager of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl, since 21 October 2022
Dhimant Shah

Dhimant Shah

Fund Manager of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl, since 1 December 2022

AMC details

Fund House
ITI Asset Management Limited
Total Schemes
Total AUM
₹3.58K Cr
as on 31-Dec-2022
Address
Naman Midtown “A” Wing, 21st Floor, Senapati Bapat Marg, Elphinstone Road
Phone
022-66214999
Email
mfassist@itiorg.com

Fund Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
Fund Allocations

Fund Allocations

This fund has an allocation of 98.89% in Equity, 0% in Debt and 1.11% in Cash related instruments
AUM size ₹165 Cr

AUM size ₹165 Cr

This fund has AUM of ₹165 Cr which is less than its category average of ₹ 1318 Cr
Expense Ratio 0.3%

Expense Ratio 0.3%

This fund has an expense ratio of 0.3% which is less than its category average expense ratio of 1.54%

Frequently Asked Questions

The current NAV of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is 9.37 as on 03-Feb-2023.
Existing (Absolute + CAGR)
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
Absolute Returns
CAGR Returns
1 Month Returns
-2.78%
-2.78%
6 Month Returns
1.26%
1.26%
1 Year Returns
-4.81%
-4.81%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.3 as on January 2023
165 Cr as on January 2023
Sun Pharmaceuticals Industries Ltd(22.73%),Cipla Ltd(8.98%),Lupin Ltd(7.35%),Divi's Laboratories Ltd(6.74%),Dr Reddy's Laboratories Ltd(6.67%) as on January 2023
Health(95.34%),Basic Materials(3.55%),Cash Equivalent(1.11%) as on January 2023
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
1.02
-
-
As on January 2023
The alpha for ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
0.95
-
-
As on January 2023
The Beta for ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
-0.5
-
-
As on January 2023
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
13.91
-
-
As on January 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Rohan Korde,Tanay Gabhawala,Dhimant Shah are the fund managers of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl
The Exit load of ITI Pharma and Healthcare Fund Direct Reinvestment Inc Dist cum Cap Wdrl is 1%

Mutual Fund execution provided by

Technology facilitation Services provided by Finzoom Investment Advisors Pvt. Ltd. - Advisory unit. SEBI Registered Investment Advisor: INA100012190 | BASL Registration No. 1154 | BSE StarMF Platform code: 24801

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not indicative of future returns.